Loading...
•
Sep 30, 2021
CorMedix Q3 2021 Earnings Report
Reported a net loss due to increased costs related to DefenCath manufacturing.
Key Takeaways
CorMedix reported a net loss of $8.6 million, or $0.22 per share, for the third quarter of 2021, compared to a net loss of $6.6 million, or $0.22 per share, for the third quarter of 2020. The increased loss was attributed to higher costs related to the manufacturing of DefenCath.
Net loss was $8.6 million, or $0.22 per share, compared to a net loss of $6.6 million, or $0.22 per share, in Q3 2020.
Operating expenses increased by approximately 30% to $8.6 million.
R&D expense increased by approximately 62% to $4.7 million.
Total cash on hand and short-term investments as of September 30, 2021 was $72.0 million.